De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Nadia Harbeck, Ulrike Nitz, Matthias Christgen, +24

Journal of Clinical Oncology

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

Monika Graeser, Friedrich Feuerhake, Oleg Gluz, +19

Journal for ImmunoTherapy of Cancer

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Monika Graeser, Simone Schrading, Oleg Gluz, +22

Breast Cancer Research

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, +24

Clinical Cancer Research

Early response by <scp>MR</scp> imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the <scp>WSG ADAPT</scp> subtrials

Monika Graeser, Simone Schrading, Oleg Gluz, +19

International Journal of Cancer

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

Monika Graeser, Nadia Harbeck, Oleg Gluz, +15

The Breast